Ravi Parikh of the Perelman School of Medicine was interviewed about his research on the use of new and expensive immunotherapy medications to treat cancer patients considered to be ineligible for clinical trials. These older, sicker patients turned out be “about twice as likely to receive these novel immunotherapies compared to healthier patients who would have been included, and this is despite the fact that these drugs have never been studied in this particular group of individuals,” said Parikh. Furthermore, the study found “no survival difference” for trial ineligible patients receiving these treatments.

December 13, 2021 ・ From ABC Australia